Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Respiri has received a £2m grant from the UK National Institute for Health Research (NIHR) to initiate a clinical study (TEAM-care) for wheezo, its proprietary asthma monitoring platform. wheezo is a UK-registered and FDA-approved pulmonary diagnostic with software as a service (SaaS) capabilities. The grant will fund the clinical study at the King’s College (London) to evaluate the impact of remote patient monitoring (RPM) to manage asthma in paediatric patients. Positive clinical data from this study would support Respiri’s aim to launch this into other markets. At end March 2022, Respiri had gross cash of A$1m and in June it raised a further A$1.7m.
Written by
Respiri |
NIHR funding to seek better outcomes
|
Healthcare |
QuickView
13 July 2022 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
|
||||||||||||||||||||||||||
Respiri has received a £2m grant from the UK National Institute for Health Research (NIHR) to initiate a clinical study (TEAM-care) for wheezo, its proprietary asthma monitoring platform. wheezo is a UK-registered and FDA-approved pulmonary diagnostic with software as a service (SaaS) capabilities. The grant will fund the clinical study at the King’s College (London) to evaluate the impact of remote patient monitoring (RPM) to manage asthma in paediatric patients. Positive clinical data from this study would support Respiri's aim to launch this into other markets. At end March 2022, Respiri had gross cash of A$1m and in June it raised a further A$1.7m.
Respiri has developed a novel diagnostics technology, wheezo platform, to support the monitoring and maintenance of irregular breathing patterns (wheeze) in asthma and chronic obstructive pulmonary disease (COPD) patients. Asthma and COPD are estimated to inflict roughly 300 million individuals globally and more than 15 million American adults, respectively. As a physiological measure and a critical component of care, these services qualify for reimbursement in the United States under the Centers for Medicare & Medicaid Services (CMS).
The company’s monitoring platform qualifies for CMS reimbursement. Physicians can be reimbursed roughly c US$2,000–2,500 per year, per patient through both RPM and chronic care management services. The monitoring and compliance services are currently outsourced to a trusted third-party RPM partner for roughly US$80 per patient, per month. More regular monitoring is anticipated to improve outcomes.
The TEAM-care trial will assess wheezo as a device to effectively monitor asthma against a standard integrated care approach. The randomised, 30-month trial will recruit c 1,500 patients and aims to build clinical and health economic evidence for UK national health service (NHS) adoption. The key primary endpoint for the trial will be to measure cost effectiveness through unscheduled NHS use with secondary endpoints including child health quality of life, asthma control and rate of NHS use. The trial is expected to start in CY Q422, with final readouts expected by end CY23. The integration of new technologies into the UK health system requires significant clinical and economical evidence. However, positive readouts should help support clinical adoption of the RPM system.
We believe positive readouts from the new UK trial and integration into further clinical studies within the United States will be important future catalysts.
EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
||||||||||||
|
||||||||||||
Research: TMT
The MISSION Group’s H1 trading update shows it is on track to meet FY22 guidance, with profits weighted, as is usual, to the second half. The trading backdrop is becoming more difficult, but the group’s collaborative approach is reaping rewards in new business and in cross-selling opportunities. The client mix is also less weighted than peers to big-brand consumer names and more towards larger industrial and blue-chip names such as Aviva. The MISSION’s strengthened balance sheet allows for flexibility for organic investment and further bolt-on acquisitions to add capabilities or technologies. The share price has outperformed peers year to date, but the shares continue to trade at a substantial discount.